We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tau Capital Plc | LSE:TAU | London | Ordinary Share | IM00B1VVFG94 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00175 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMTAU
RNS Number : 2557L
Tau Capital PLC
30 September 2016
TAU CAPITAL PLC
CONDENSED HALF-YEARLY REPORT AND UNAUDITED CONDENSED COMPANY FINANCIAL STATEMENTS FOR THE SIX MONTHSED 30 JUNE 2016
Chairman's Statement
Your Board continues to try and dispose of the one remaining investment, Stopharm LLC ("Stopharm"), in a way which best serves the interests of our shareholders as announced on 22 September 2016.
Although a sale to Capitalgate Securities Limited has not progressed, we understand that this still remains a possibility albeit the timing and the consideration are uncertain. The downturn in the Kazakhstan economy and, in particular, the material devaluation in the Tenge in 2015 has meant that transactions which might have taken place have been delayed. However, the financial performance of Stopharm is improving and is being helped by an apparent stabilising of the Tenge against the US Dollar. It is hoped that this stabilisation will continue and that it will be possible to sell Stopharm at an acceptable price.
In the meantime, the Board is holding discussions with other third parties and exploring other avenues for selling the asset and realising value for shareholders.
The Board is also in the process of further cutting the running costs of the Company.
Thank you again for your continuing support.
Philip Lambert
Chairman
29 September 2016
Investment Advisor's Report
Private Equity Holdings held by the indirect subsidiaries of Tau Capital Plc
Indirect subsidiaries
Tau SPV 1 Cooperatief W.A. % Ownership Valuation
Stopharm LLP 40.35% $6 m
Stopharm LLP
Financial Results
During for the first 6 months of 2016 year, Stopharm LLP earned revenues of US$64.7 million which was a slight increase compared to 2015 (annualized). See note 4(i) for further detail on Stopharm LLP.
Hot Features
Premium
2015 6 months Annualized
Audited to forecast
US$000's June 2016 2016
US$000`s US$000's
------------------ --------- ---------- ----------
Revenue 109,730 64,758 129,500
------------------ --------- ---------- ----------
EBITDA 3,010 2,273 4,500
------------------ --------- ---------- ----------
Interest on loans (2,277) (1,312) (2,620)
------------------ --------- ---------- ----------
Corporate Tax (249) - 0
------------------ --------- ---------- ----------
Net Profit/(loss) 227 961 1,922
------------------ --------- ---------- ----------
The 6 months to June 2016 figures are based on the unaudited management accounts produced by Stopharm LLP.The US dollar amounts used above are based upon a Kazakhstan Tenge to US Dollar rate of 339.18 to 1. The comparative rate used for the 2015 Interims was 185.35 to 1.
The Tenge has shown signs of stabilising and at the date of signing the Statement of Financial Position the Tenge to US Dollar rate was 337.74.
Condensed Company Statement of Comprehensive Income
For the For the
six months For the six months
ended year ended ended
30 June 31 December 30 June
2016 2015 2015
(Unaudited) (Audited) (Unaudited)
Note US$ US$ US$
Investment income
Interest income 6 17 5
Dividend income - -
Net (loss) on financial
assets and liabilities
at fair value through
profit or loss (8,751) (1,044,966) (46,284)
Total operating
(loss) (8,745) (1,044,949) (46,279)
------------ ------------- ------------
Expenses
Operating expenses 8 (307,853) (598,457) (238,918)
------------ ------------- ------------
(Loss) for the
period/year: (316,598) (1,643,406) (285,197)
Total comprehensive
(loss)
for the period/year
attributable to
shareholders (316,598) (1,643,406) (285,197)
============ ============= ============
Basic and diluted
(loss) per share 13 ($0.01) ($0.03) ($0.01)
All results derive from continuing operations.
The accompanying notes on pages 8 to 15 are an integral part of these condensed financial statements.
Condensed Company Statement of Financial Position
As at As at As at
30 June 31 December 30 June
2016 2015 2015
(Unaudited) (Audited) (Unaudited)
Note US$ US$ US$
Assets
Cash 40,003 97,481 369,583
Debtors and prepayments 68,049 49,469 71,644
Loan to subsidiary 6 35,761 108,699 142,509
Investments in
subsidiaries 4 7,600,997 7,609,748 8,608,430
Total assets 7,744,810 7,865,397 9,192,166
------------- ------------- -------------
Liabilities
Creditors and accruals (107,852) (103,857) (72,417)
Loan from subsidiary 6 (192,016) - -
Total liabilities (299,868) (103,857) (72,417)
------------- ------------- -------------
Total net assets 7,444,942 7,761,540 9,119,749
============= ============= =============
Shareholders' equity
Share capital 5 976,209 976,209 976,209
Distributable reserves 6,468,733 6,785,331 8,143,540
Total shareholders'
equity 7,444,942 7,761,540 9,119,749
============= ============= =============
Net Asset Value
per share $0.15 $0.18 $0.19
Approved by the Board of Directors and signed on its behalf by:
Philip Scales Philip Lambert
29 September 2016
The accompanying notes on pages 8 to 15 are an integral part of these condensed financial statements.
Condensed Company Statement of Changes in Equity for the
six months ended 30 June 2016
Share Distributable
capital reserves Total
(Unaudited) (Unaudited) (Unaudited)
US$ US$ US$
Balance at 31 December
2015 976,209 6,785,331 7,761,540
Total comprehensive
(loss) for the period - (316,598) (316,598)
------------ -------------- -------------
Balance at 30 June 2016 976,209 6,468,733 7,444,942
============ ============== =============
Condensed Company Statement of Changes in Equity for the
year ended 31 December 2015
Share Distributable
capital reserves Total
(Audited) (Audited) (Audited)
US$ US$ US$
Balance at 31 December
2014 976,209 8,428,737 9,404,946
Total comprehensive
(loss) for the year - (1,643,406) (1,643,406)
---------- -------------- ------------
Balance at 31 December
2015 976,209 6,785,331 7,761,540
========== ============== ============
Condensed Company Statement of Changes in Equity for the
six months ended 30 June 2015
Share Distributable
capital reserves Total
(Unaudited) (Unaudited) (Unaudited)
US$ US$ US$
Balance at 31 December
2014 976,209 8,428,737 9,404,946
Total comprehensive
(loss) for the period - (285,197) (285,197)
------------ -------------- -------------
Balance at 30 June 2015 976,209 8,143,540 9,119,749
============ ============== =============
The accompanying notes on pages 8 to15 are an integral part of these condensed financial statements.
Condensed Company Statement of Cash Flows for the
six months ended 30 June 2016
For the For the For the
six months year ended six months
ended 30 31 December ended 30
June 2016 2015 June 2015
(Unaudited) (Audited) (Unaudited)
US$ US$ US$
Cash flows from operating
activities
(Loss) for the period/year (316,598) (1,643,406) (285,197)
Adjustments to reconcile
(loss) for the period/year
to net cash provided
by operating activities
(Increase)/decrease
in debtors and prepayments (18,580) 1,345 (20,830)
Decrease in investments
in subsidiaries 8,751 1,044,966 46,284
Increase/(decrease)
in creditors and accruals 3,995 (21,794) (53,234)
Decrease in loans to
subsidiaries 264,954 886 -
Net cash (used in) operating
activities (57,478) (618,003) (312,977)
------------ ------------- ------------
Cash flows from financing
activities
(Payment) for purchase
of ordinary shares - - -
(Payment)/proceeds from
inter-company loan - - (32,924)
Net cash (used in)/from
financing activities - - (32,924)
------------ ------------- ------------
Net (decrease) in cash
and cash equivalents (57,478) (618,003) (345,901)
Cash and cash equivalents
at the beginning of
period/year 97,481 715,484 715,484
Cash and cash equivalents
at the end of period/year 40,003 97,481 369,583
============ ============= ============
Supplementary disclosure
of cash flow information
Dividends received - - -
The accompanying notes on pages 8 to 15 are an integral part of these condensed financial statements.
Condensed Notes to the Financial Statements
1. General
Tau Capital plc (the "Company") is a closed-ended investment fund incorporated and domiciled in the Isle of Man on 3 April 2007. The Company was incorporated under the Companies Acts 1931-2004. Following approval at the AGM held on 24 July 2012, the Company was re-registered under the Companies Act 2006 with number 008604V. The Company was originally established to allow investors the opportunity to realise returns through investing in both public and private businesses that are established in, operating in or have exposure to Kazakhstan. Although Kazakhstan focused, the Company also sought investment opportunities in the Kyrgyz Republic, Uzbekistan, Turkmenistan, Tajikistan, Mongolia and Russia (the "Investment Countries"). The Company is listed on the AIM (formerly the Alternative Investment Market) of the London Stock Exchange. The Company has no employees.
The Company's investments are held by direct and indirect subsidiaries. Tau (Cayman) L.P., a direct subsidiary, holds one private investments as at the period end date (31 December 2015: one; 30 June 2015: one). Tau SPV 1 Cooperatief W.A., an indirect subsidiary, holds one private investment (31 December 2015: one; 30 June 2015: one)
The Group is currently implementing the investing policies agreed at the 2012 AGM and has not made any new investments during the period under review.
2. Statement of compliance
These interim consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all of the information required for full annual financial statements, and should be read in conjunction with consolidated financial statements of the Company as at the year ended 31 December 2015.
The consolidated financial statements of the Company as at and for the year ended 31 December 2015 are available upon request from the Company's registered office at IOMA House, Hope Street, Douglas, Isle of Man IM1 1AP or at www.taucapitalplc.com.
3. Significant accounting Policies
The accounting policies applied in these interim financial statements are the same as those applied in the Company's consolidated financial statements as at 31 December 2015.
There are no IFRS or IFRIC interpretations that are not yet effective that would be expected to have a material impact to the Company.
4. Investments in Subsidiaries
Direct Subsidiaries
The Company holds the following investments in subsidiaries:
Principal Proportion
Name Country investment of
ownership
of incorporation activity interest
-------------- ------------------ ---------------- -----------
Tau (Cayman) Investment
L.P. Cayman Islands holding 100%
Tau Cayman
Ltd Cayman Islands Administration 100%
-------------- ------------------ ---------------- -----------
Indirect Subsidiaries
The subsidiary company Tau (Cayman) L.P. in turn holds the following investment in subsidiary:
Principal Proportion
Name Country investment of
ownership
of incorporation activity interest
-------------- ------------------ ------------- -----------
Tau SPV 1
Cooperatief Investment
W.A. The Netherlands holding 99%
-------------- ------------------ ------------- -----------
Condensed Notes to the Financial Statements (continued)
4. Investments in Subsidiaries (continued)
The fair values of the subsidiaries of the Company at 30 June 2016, 31 December 2015 and 30 June 2015 were as follows:
As at As at As at
30 June 31 December 30 June
2016 2015 2015
US$ US$ US$
Tau (Cayman) L.P. (including
its subsidiary TAU SPV
1 Cooperatief W.A.) 7,600,997 7,609,748 8,608,430
7,600,997 7,609,748 8,608,430
---------- ------------ ----------
The Company classifies investments in subsidiaries in accordance with IAS 39 - Financial Instruments: Recognition and Measurement and values its investments in subsidiaries in accordance with IFRS 13 - Fair Value Measurements ("IFRS 13"). IFRS 13 defines fair value and establishes a framework for measuring fair value.
Financial instruments included in each category are as follows:
Level 1 - Quoted market price
Level 2 - Market observable inputs
Level 3 - Non-market observable inputs
The following tables show an analysis of financial instruments recorded at fair value, between those whose fair value is based on quoted market prices (level 1), those involving valuation techniques where all the model inputs are observable in the market (level 2) and those where the valuation technique involves the use of non-market observable inputs (level 3).
As at 30 June 2016, the breakdown was as follows:
(Level (Level (Level Total
1) 2) 3)
US$ US$ US$ US$
Financial Assets
- Designated at fair
value
through profit or
loss - - 7,600,997 7,600,997
-------- -------- ---------- ----------
- - 7,600,997 7,600,997
-------- ------------------------------- ---------- ----------
As at 31 December 2015, the breakdown was as follows:
(Level (Level (Level Total
1) 2) 3)
US$ US$ US$ US$
Financial Assets
- Designated at fair
value
through profit or
loss - - 7,609,748 7,609,748
-------- -------- ---------- ----------
- - 7,609,748 7,609,748
-------- ------------------------------- ---------- ----------
As at 30 June 2015, the breakdown was as follows:
(Level (Level (Level Total
1) 2) 3)
US$ US$ US$ US$
Financial Assets
- Designated at fair
value
through profit or
loss - - 8,608,430 8,608,430
-------- -------- ---------- ----------
- - 8,608,430 8,608,430
-------- ------------------------------- ---------- ----------
There were no transfers between level 1 and 2 in the period.
Condensed Notes to the Financial Statements (continued)
4. Investments in Subsidiaries (continued)
The following is a reconciliation of the movement in financial assets for which non-market observable inputs (level 3) were used to determine fair value as at 30 June 2016, 31 December 2015 and 30 June 2015:
30 June 31 December 30 June
2016 2015 2015
US$ US$ US$
Opening balance
at beginning
of period 7,609,748 8,654,714 8,654,714
Net unrealised
(loss) on investments (8,751) (1,044,966) (46,284)
------------------- ------------------- -------------------
Closing balance
at end of period 7,600,997 7,609,748 8,608,430
------------------- ------------------- -------------------
Net realised and unrealised gains/(losses) on investments are recognised as investment income in the Statement of Comprehensive Income. There were no transfers out of level 3 during the period (31 December 2015: none, 30 June 2015: none).
Fair value of the Company's level 3 financial assets and financial liabilities that are measured at fair value on a recurring basis
Some of the Company's financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used).
Financial Fair value Fair Valuation Significant Relationship
assets as at 30 value techniques unobservable of unobservable
June 2016 hierarchy and input inputs
key to fair
inputs value
--------------- --------------------- ----------- ------------ --------------------- -----------------
Investment 100% investment Level Net Tau (Cayman) The higher
in subsidiary in Tau 3 realisable L.P. holds the valuation
(Cayman) assets an investment of investments
L.P.: approach in a in unlisted
US$7,600,997 subsidiary private
(31 December TAU SPV 1 companies,
2015:US$7,609,748, Cooperatief the higher
30 June W.A. ("Tau the fair
2015: US$8,608,430) SPV 1") which value.
is an
indirect subsidiary
of the
Company. Tau
SPV 1
also holds
an investment
in an unlisted
private
company valued
at
US$6,000,000
as at 30
June 2016.
The net
assets are
predominantly
based on the
valuation
of
an underlying
private
company investment,
which is based
on unobservable
inputs as
detailed below.
--------------- --------------------- ----------- ------------ --------------------- -----------------
If the value of the unlisted private company investments held by Tau SPV 1 Cooperatief W.A., the subsidiary if Tau (Cayman) L.P. and indirect subsidiary of the Company, were 10 per cent higher/lower while all the other variables were held constant, the carrying amount of the investment held would increase/decrease by US$600,000 (31 December 2015: US$600,000, 30 June 2015: US$700,000).
Tau Cayman Limited has no assets or liabilities and a fair value of US$Nil (31 December 2015: US$Nil, 30 June 2015: US$Nil). A sensitivity to changes in assumptions has therefore not been prepared in respect of the investment in Tau Cayman Limited.
Condensed Notes to the Financial Statements (continued)
4. Investments in Subsidiaries (continued)
Tau (Cayman) L.P.
As noted above, the fair value of Tau (Cayman) L.P. is based on the net assets of Tau (Cayman) L.P. As at 30 June 2016, 31 December 2015 and 30 June 2015, the assets and liabilities of Tau (Cayman) L.P. were as follows:
As at As at As at
30 June 31 December 30 June
2016 2015 2015
US$ US$ US$
Cash 1,446,432 1,757,255 1,766,678
Debtors and prepayments 2,750 - 2,750
Financial assets
at fair value through
profit or loss - - -
Investment in subsidiary 5,959,799 5,960,477 6,946,986
Loan to parent 192,016 - -
Total assets 7,600,997 7,717,732 8,716,414
Accounts payable
and accrued expenses - -
Loan from parent - (107,984) (107,984)
---------- ------------ ----------
Total liabilities - (107,984) (107,984)
Total net assets 7,600,997 7,609,748 8,608,430
---------- ------------ ----------
Tau SPV 1 Cooperatief W.A. - direct subsidiary of Tau (Cayman) L.P and indirect subsidiary of the Company
The fair value of Tau SPV 1 Cooperatief W.A. ("Tau SPV 1") is based on the net asset of Tau SPV 1. As at 30 June 2016, 31 December 2015 and 30 June 2015, the assets and liabilities of Tau SPV 1 were as follows:
As at As at As at
30 June 31 December 30 June
2016 2015 2015
US$ US$ US$
Cash 10,576 891 8,949
Debtors and prepayments - - -
Financial assets
at fair value through
profit or loss 6,000,000 6,000,000 7,000,000
Total assets 6,010,576 6,000,891 7,008,949
Accounts payable
and accrued expenses (15,016) (21,699) (16,930)
Loan to group company - (18,000) -
Loan from parent (35,761) (715) (45,033)
---------- ------------ ----------
Total liabilities (50,777) (40,414) (61,963)
Total net assets 5,959,799 5,960,477 6,946,986
---------- ------------ ----------
Condensed Notes to the Financial Statements (continued)
4. Investments in Subsidiaries (continued)
At the period end, the Tau (Cayman) L.P.'s investment portfolio of financial assets at fair value through profit or loss held by the direct and indirect subsidiaries of the Company comprised one (31 December 2015: one; 30 June 2015: one) investments as follows:
As at As at As at
30 June 31 December 30 June
2016 2015 2015
Investment
type Note US$ US$ US$
Private
Stopharm LLP investment (i) 6,000,000 6,000,000 7,000,000
Total 6,000,000 6,000,000 7,000,000
---------- ------------ ----------
The Directors of the direct and indirect subsidiaries and the Company have valued private investments held by the direct and indirect subsidiaries of the Company on the advice of the Investments Advisor and using the guidance laid down in the International Private Equity and Venture Capital Valuation Guidelines (December 2012) ("IPEVCVG"). The following table gives information about the fair values of these financial assets and in particular, the valuation techniques and inputs, as at 30 June 2016.
Financial Fair value as at Fair value Valuation
assets 30 June 2016 hierarchy techniques
and key inputs
Private 40.35 per cent Level 3 Indicative
equity equity investment offer
investments in Stopharm LLP
engaged in wholesale
pharmaceutical
distribution: US$6,000,000
(i) Stopharm LLP ("Stopharm")
Stopharm is a wholesale pharmaceuticals distributor operating in Kazakhstan. On 1 September 2010, the Group announced the closing of a US$21.5 million investment in Stopharm comprising a 24.00% equity stake in Stopharm acquired for US$12.8 million and a fully secured convertible bridge loan of US$8.7 million provided to one of the shareholders of Stopharm with implied equity on conversion representing an additional 16.35% stake. The conversion into equity of this loan was subject to approval by the Anti-Monopoly Committee of the Republic of Kazakhstan which was received on 25 November 2011. The conversion subsequently took place on 27 December 2011.
The investment in Stopharm LLP has been valued at 30 June 2016 at US$6,000,000 (31 December 2015: US$6,000,000). The valuation is based on an enterprise value which is calculated on a multiple range of 6 to 16 times EBITDA. The value of US$6,000,000 (30 June 2015: US$7,000,000; valued on an indicative offer from a related party) has been estimated by the Directors of the indirect subsidiary following the opinions and advice of the Investment Advisor in the absence of readily available market values. The Directors of the Company agree with these estimates. Due to the uncertainty arising from the lack of comparable listed companies or recent transactions involving similar businesses on which to determinate the multiple applied against earnings used as a basis for the valuation, the estimated values may differ materially from the value that would have been realised had a disposal of the private investment been made between a willing buyer and seller as at 30 June 2016, which in turn would have an impact on the valuation of the Company's investment in subsidiaries. It is not possible to qualify such uncertainties.
Condensed Notes to the Financial Statements (continued)
4. Investments in Subsidiaries (continued)
(i) Stopharm LLP ("Stopharm") (continued)
On 14 November 2014, under the terms of a Members Contribution Agreement, Tau (Cayman) L.P. made an additional contribution in kind to the capital of Tau SPV 1 Cooperatief W.A. ("Tau SPV 1") by
way of a transfer of its participation interest equal to 40.35% of the charter capital of Stopharm LLP for a value of US$7,000,000.
In relation to the investment held by Tau SPV 1 in Stopharm LLP, valued at US$6,000,000, (31 December 2015: US$6,000,000; 30 June 2015: US$7,000,000) where the valuation of investment is dependent on non-market observable inputs, in this instance an indicative offer from a related party, a degree of judgement is required in estimating fair values. It is reasonably possible that outcomes within the next financial year that are different from the assumptions adopted by the Board of Directors of Tau SPV 1 and the Company could require a material adjustment to the carrying amount of the asset affected. Accordingly, the valuation of the underlying private investment is subject to significant inherent uncertainty. This in turn creates significant uncertainty in relation to the value of the Company's investment in subsidiaries, as Tau (Cayman) L.P. owns Tau SPV 1.
5. Share Capital and Share Premium
The authorised share capital of the Company is GBP3,502,000 comprising 350,199,998 ordinary shares of GBP0.01 each and 2 founder shares of GBP0.01 each. The founder shares carry identical rights and privileges to the ordinary shares of the Company which includes a right to receive all dividends and other distributions declared, made or paid. The share capital of the Company has been allocated, called up and fully paid. The shares in issue as at 30 June 2016, 31 December 2015 and 30 June 2015 were as follows:
Ordinary Founder
Shares Shares
in issue in issue
As at 30 June 2016 48,984,680 2
As at 31 December
2015 48,984,680 2
As at 30 June 2015 48,984,680 2
6. Intercompany loan
As at 30 June 2016, the Company had loaned Tau (Cayman) L.P. an amount of US$Nil (31 December 2015: US$107,984, 30 June 2015: US$142,509) for the payment of day to day expenses. The loan is interest free, unsecured and repayable on demand.
As at 30 June 2016, the Company received from Tau (Cayman) L.P. an amount of US$300,000 (31 December 2015: US$Nil, 30 June 2015: US$Nil) for the payment of day to day expenses. The loan is interest free, unsecured and repayable on demand.
As at 30 June 2016, the Company had loaned Tau SPV 1 Cooperatief W.A. an amount of US$35,046 (31 December 2015: US$715, 30 June 2015: US$34,525) for the payment of day to day expenses. The loan is interest free, unsecured and repayable on demand.
Condensed Notes to the Financial Statements (continued)
7. Related Party Items
Philip Scales, a Director of the Company as listed on page 1, is the managing director of FIM Capital Limited (formerly IOMA Fund and Investment Management Limited), the Administrator.
As at 30 June 2016, Philip Lambert, a Director of the Company, held 101,201 ordinary shares in the Company (31 December 2015, 101,201 and 30 June 2015, Philip Lambert held 101,201 ordinary shares).
As at 30 June 2016, Richard Horlick, a previous director of the Company who was retained after his retirement on 1 January 2014 to act in a consultancy capacity, held 12,684,221 ordinary shares (31 December 2015: 12,684,221 and June 2015: 12,684,221).
As at 30 June 2016, Terence Mahony, a Director of the Company, held 102,424 ordinary shares (31 December 2015: 102,424; 30 June 2015: 102,424).
As at 30 June 2016, 31 December 2015 and 30 June 2015, both Spencer House Capital Management LLP and Compass Asset Management Ltd held one founder share each.
8. Fees & Expenses
Directors' remuneration
Directors' remuneration for the period ended 30 June 2016 amounted to US$42,800 (31 December 2015: US$93,605; 30 June 2015: US$47,329).
Administrator fees
The Administrator is entitled to receive a fixed fee of GBP35,000 for provision of administration services and US$35,000 for provision of accounting services per annum payable quarterly in arrears.
The Administrator's fees for the period ended 30 June 2016 amounted to US$47,076.34 (31 December 2015: US$99,333; 30 June 2015: US$50,033).
All investment management fees are borne by subsidiaries of the Company.
9. Exchange Rates
The following exchange rates were used to translate assets and liabilities into US dollars at 30 June 2016, 31 December 2015 and 30 June 2015:
As at As at As at
30 June 31 December 30 June
2016 2015 2015
Euro 1.1107 1.0856 1.11470
Pound sterling 1.3316 1.4736 1.57125
Condensed Notes to the Financial Statements (continued)
10. Distributions
Subject to the provisions of the Articles, the Company may by ordinary resolution, declare that out of profits available for distribution, in accordance with Isle of Man law, dividends be paid to members according to their respective rights and interests in the profits of the Company. However, no dividend shall exceed the amount recommended by the Board. There is no fixed date on which an entitlement to dividend arises.
No dividends were declared or paid during the periods/year ended 30 June 2016, 31 December 2015 or 30 June 2015.
11. Soft Commissions
During the period, the Investment Managers, Investment Advisors and connected persons have not entered into soft commission arrangements with brokers in respect of which certain goods and services used to support investment decision making were received.
12. Commitments and Contingent Liabilities
As at 30 June 2016, the Group has no commitments and contingent liabilities (31 December 2015: US$Nil; 30 June 2015: US$Nil).
13. (Loss) per Share
Basic and diluted loss per share is calculated by dividing the net profit or loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period/year.
For the For the
six months For the six months
ended year ended ended
30 June 31 December 30 June
2016 2015 2015
Net (loss) attributable
to shareholders (US$316,598) (US$1,643,406) (US$285,197)
Weighted average number
of
ordinary shares in
issue 48,984,680 48,984,680 48,984,680
Basic (loss) per share ($0.01) ($0.03) ($0.01)
There is no difference between the fully diluted earnings per share and basic earnings per share.
14. Events After the Date of the Statement of Financial Position
There were no events occurring after the date of the Statement of Financial Position that would have a material impact on this interim report.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR UKVVRNUAKUAR
(END) Dow Jones Newswires
September 30, 2016 02:00 ET (06:00 GMT)
1 Year Tau Capital Chart |
1 Month Tau Capital Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
